Increased survival associated with radiolabeled lym‐1 therapy for non‐hodgkin's lymphoma and chronic lymphocytic leukemia
暂无分享,去创建一个
G L DeNardo | K. Lamborn | G. Denardo | S. Denardo | S J DeNardo | K R Lamborn | D S Goldstein | L A Kroger | D. Goldstein | L. Kroger | Sally J. DeNardo | Kathleen R. Lamborn | Gerald L. DeNardo | Linda A. Kroger
[1] I. Bernstein,et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas , 1995, The Lancet.
[2] G. Denardo,et al. Radioimmunotherapy of lymphoma: a UC Davis experience. , 1995, Hybridoma.
[3] G. Denardo,et al. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. , 1995, Cancer research.
[4] K. Lamborn,et al. Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies. , 1994, Cancer research.
[5] G. Denardo,et al. Effect of lym‐1 radioimmunoconjugate on refractory chronic lymphocytic leukemia , 1994, Cancer.
[6] I. Bernstein,et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. , 1993, The New England journal of medicine.
[7] M. Czuczman,et al. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Kaminski,et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. , 1993, The New England journal of medicine.
[9] R. Meredith,et al. Comparison of diagnostic and therapeutic doses of 131I-LYM-1 in patients with non-Hodgkin's lymphoma , 1993 .
[10] A. M. Zimmer,et al. A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1. , 1993, Cancer biotherapy.
[11] D. Goldenberg,et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Winter,et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. , 1987, Cancer research.
[13] J. McGahan,et al. Treatment of a Patient with b Cell Lymphoma by 1-131 Lym-1 Monoclonal Antibodies , 1987, The International journal of biological markers.
[14] J R Anderson,et al. Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] G. Denardo,et al. Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development. , 1986, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[16] M. Buyse,et al. Cancer Clinical Trials: Methods and Practice. , 1985 .
[17] M. Shapiro,et al. Reporting results from chemotherapy trials. Does response make a difference in patient survival? , 1984, JAMA.
[18] J. Hokanson,et al. Comparing survival of responders and nonresponders after treatment: a potential source of confusion in interpreting cancer clinical trials. , 1983, Controlled clinical trials.